Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Biomarkers in Perinatal Diseases
share announcement

Biomarkers in Perinatal Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 3682

Special Issue Editor

Dr. Sebastian Kwiatkowski

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Pomeranian Medical University in Szczecin, Szczecin, Poland
Interests: preeclampsia; FGR; placental insufficiency; placental invasion; angiogenesis markers; ultrasound; perinatal outcomes; placental aging; placental malperfusion
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Today's perinatal medicine uses the latest technological solutions. Its aim is to properly stratify high-risk groups, which should be subject to special supervision and care. The first breakthrough was the implementation of ultrasound diagnostics for general use, currently models are being constructed which, in addition to biophysical methods, are supplemented with biochemical and genetic parameters.

Biomarkers play an increasingly important role in both screening and final diagnosis. The increasing sensitivity of laboratory methods, as well as the possibility of isolating the parameters of the uteroplacental compartment in areas available for diagnostics, such as maternal blood, vaginal secretions or after invasive diagnostics, such as amniocentesis, chorionic villus sampling, provide unprecedented opportunities to expand knowledge about the processes occurring inside the developing pregnancy

All this makes our knowledge broader and our actions more precise
The aim of the issue is to draw attention to the usefulness of broadly understood biomarkers in clinical practice.

Dr. Sebastian Kwiatkowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Prenatal screening
  • prenatal diagnostic
  • biomarkers
  • fetal-maternal compartment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1939 KiB  
Article
Stratification of Amniotic Fluid Cells and Amniotic Fluid by Sex Opens Up New Perspectives on Fetal Health
by Ilaria Campesi, Giampiero Capobianco, Antonella Cano, Valeria Lodde, Sara Cruciani, Margherita Maioli, Giovanni Sotgiu, Maria Laura Idda, Mariangela Valentina Puci, Margherita Ruoppolo, Michele Costanzo, Marianna Caterino, Francesca Cambosu, Andrea Montella and Flavia Franconi
Biomedicines 2023, 11(10), 2830; https://doi.org/10.3390/biomedicines11102830 - 18 Oct 2023
Cited by 2 | Viewed by 1442
Abstract
Amniotic fluid is essential for fetus wellbeing and is used to monitor pregnancy and predict fetal outcomes. Sex affects health and medicine from the beginning of life, but knowledge of its influence on cell-depleted amniotic fluid (AF) and amniotic fluid cells (AFCs) is [...] Read more.
Amniotic fluid is essential for fetus wellbeing and is used to monitor pregnancy and predict fetal outcomes. Sex affects health and medicine from the beginning of life, but knowledge of its influence on cell-depleted amniotic fluid (AF) and amniotic fluid cells (AFCs) is still neglected. We evaluated sex-related differences in AF and in AFCs to extend personalized medicine to prenatal life. AFCs and AF were obtained from healthy Caucasian pregnant women who underwent amniocentesis at the 16th–18th week of gestation for advanced maternal age. In the AF, inflammation biomarkers (TNFα, IL6, IL8, and IL4), malondialdehyde, nitrites, amino acids, and acylcarnitines were measured. Estrogen receptors and cell fate (autophagy, apoptosis, senescence) were measured in AFCs. TNFα, IL8, and IL4 were higher in female AF, whereas IL6, nitrites, and MDA were similar. Valine was higher in male AF, whereas several acylcarnitines were sexually different, suggesting a mitochondrial involvement in establishing sex differences. Female AFCs displayed higher expression of ERα protein and a higher ERα/ERβ ratio. The ratio of LC3II/I, an index of autophagy, was higher in female AFCs, while LC3 gene was similar in both sexes. No significant sex differences were found in the expression of the lysosomal protein LAMP1, while p62 was higher in male AFCs. LAMP1 gene was upregulated in male AFCs, while p62 gene was upregulated in female ones. Finally, caspase 9 activity and senescence linked to telomeres were higher in female AFCs, while caspase 3 and β-galactosidase activities were similar. This study supports the idea that sex differences start very early in prenatal life and influence specific parameters, suggesting that it may be relevant to appreciate sex differences to cover knowledge gaps. This might lead to improving the diagnosis of risk prediction for pregnancy complications and achieving a more satisfactory monitoring of fetus health, even preventing future diseases in adulthood. Full article
(This article belongs to the Special Issue Biomarkers in Perinatal Diseases)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

18 pages, 879 KiB  
Review
Low-Dose Aspirin after ASPRE—More Questions Than Answers? Current International Approach after PE Screening in the First Trimester
by Piotr Tousty, Magda Fraszczyk-Tousty, Sylwia Dzidek, Hanna Jasiak-Jóźwik, Kaja Michalczyk, Ewa Kwiatkowska, Aneta Cymbaluk-Płoska, Andrzej Torbé and Sebastian Kwiatkowski
Biomedicines 2023, 11(6), 1495; https://doi.org/10.3390/biomedicines11061495 - 23 May 2023
Cited by 1 | Viewed by 1943
Abstract
Preeclampsia (PE) is a multi-factorial disorder of pregnancy, and it continues to be one of the leading causes of fetal and maternal morbidity and mortality worldwide. Aspirin is universally recommended for high-risk women to reduce preeclampsia risk. The purpose of this review is [...] Read more.
Preeclampsia (PE) is a multi-factorial disorder of pregnancy, and it continues to be one of the leading causes of fetal and maternal morbidity and mortality worldwide. Aspirin is universally recommended for high-risk women to reduce preeclampsia risk. The purpose of this review is to summarize the recommendations of various scientific societies on predicting preeclampsia and their indications for the inclusion of acetylsalicylic acid (ASA) prophylaxis. Fourteen guidelines were compared. The recommended dose, screening method, and gestational age at the start of the test vary depending on the recommendation. The societies are inclined to recommend using increasingly higher doses (>75 mg) of ASA, with many encouraging doses from 100 mg upward. Most societies indicate that the optimal time for implementing aspirin is prior to 16 weeks’ gestation. Following the publication of the Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) trial results and other papers evaluating the Fetal Medicine Foundation (FMF) screening model, a large number of societies have changed their recommendations from those based on risk factors alone to the ones based on the risk assessment proposed by the FMF. This allows for the detection of a high-risk pregnancy population in whom aspirin will be remarkably effective in preventing preterm PE, thereby decreasing maternal and fetal morbidity. Full article
(This article belongs to the Special Issue Biomarkers in Perinatal Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop